Patrick Miles Sells 43,459 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 43,459 shares of the company’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total transaction of $519,335.05. Following the completion of the sale, the chief executive officer now directly owns 6,065,772 shares in the company, valued at approximately $72,485,975.40. This represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Patrick Miles also recently made the following trade(s):

• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The shares were sold at an average price of $12.03, for a total transaction of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total value of $80,244.00.

Alphatec Price Performance

Shares of ATEC opened at $11.36 on Friday. The business’s fifty day moving average is $10.26 and its 200 day moving average is $8.13. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The stock has a market cap of $1.61 billion, a P/E ratio of -8.88 and a beta of 1.43.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ATEC shares. Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Needham & Company LLC raised their price objective on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. increased its position in shares of Alphatec by 0.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after acquiring an additional 1,120 shares in the last quarter. Atria Investments Inc increased its holdings in Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Alphatec by 1.3% in the fourth quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company’s stock worth $1,277,000 after purchasing an additional 1,746 shares during the last quarter. Entropy Technologies LP raised its stake in shares of Alphatec by 14.9% in the third quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock worth $120,000 after purchasing an additional 2,800 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Alphatec in the fourth quarter valued at approximately $29,000. 66.35% of the stock is owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.